Lv65
2990 积分 2024-03-07 加入
Nonclinical teratogenicity safety assessment of CRBN-engaging targeted protein degraders: Points to consider
2小时前
已完结
Finding a needle in the haystack: ADME and pharmacokinetics/pharmacodynamics characterization and optimization towards orally available bifunctional protein degraders
18天前
已完结
An update on the importance of plasma protein binding in drug discovery and development
22天前
已完结
Bridging in vitro and clinical data: Experimental insights into the IC50 variability of dolutegravir as an organic cation transporter 2 inhibitor
29天前
已关闭
Cerivastatin-induced rhabdomyolysis in a renal transplant on cyclosporin
30天前
已关闭
Carboxylated/Oxidized Diamond Nanoparticles for Quantifying Immunoglobulin G Antibodies Using Mass Spectrometry
7个月前
已完结
Current advances and development strategies of orally bioavailable PROTACs
11个月前
已完结
皖公网安备34019202002308
